121 related articles for article (PubMed ID: 8557156)
1. Clinical and hormonal effects of gonadotropin-releasing hormone agonist plus an oral contraceptive in severely hirsute patients with polycystic ovary disease.
Ciotta L; Cianci A; Giuffrida G; Marletta E; Aglianò A; Palumbo G
Fertil Steril; 1996 Jan; 65(1):61-7. PubMed ID: 8557156
[TBL] [Abstract][Full Text] [Related]
2. Treatment of hirsutism with flutamide and a low-dosage oral contraceptive in polycystic ovarian disease patients.
Ciotta L; Cianci A; Marletta E; Pisana L; Aglianò A; Palumbo G
Fertil Steril; 1994 Dec; 62(6):1129-35. PubMed ID: 7957975
[TBL] [Abstract][Full Text] [Related]
3. Clinical and hormonal effects of the combination gonadotrophin-releasing hormone agonist plus oral contraceptive pills containing ethinyl-oestradiol (EE) and cyproterone acetate (CPA) versus the EE-CPA pill alone on polycystic ovarian disease-related hyperandrogenisms.
Acién P; Mauri M; Gutierrez M
Hum Reprod; 1997 Mar; 12(3):423-9. PubMed ID: 9130733
[TBL] [Abstract][Full Text] [Related]
4. Combination gonadotropin-releasing hormone agonist and oral contraceptive therapy improves treatment of hirsute women with ovarian hyperandrogenism.
Elkind-Hirsch KE; Anania C; Mack M; Malinak R
Fertil Steril; 1995 May; 63(5):970-8. PubMed ID: 7720941
[TBL] [Abstract][Full Text] [Related]
5. Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist.
Ruchhoft EA; Elkind-Hirsch KE; Malinak R
Fertil Steril; 1996 Jul; 66(1):54-60. PubMed ID: 8752611
[TBL] [Abstract][Full Text] [Related]
6. Gonadotropin-releasing hormone analog plus an oral contraceptive containing desogestrel in women with severe hirsutism: effects on hair, bone, and hormone profile after 1-year use.
Castelo-Branco C; Martínez de Osaba MJ; Pons F; Fortuny A
Metabolism; 1997 Apr; 46(4):437-40. PubMed ID: 9109850
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome.
Falsetti L; Galbignani E
Contraception; 1990 Dec; 42(6):611-9. PubMed ID: 2150631
[TBL] [Abstract][Full Text] [Related]
8. Hormonal and clinical effects of GnRH agonist alone, or in combination with a combined oral contraceptive or flutamide in women with severe hirsutism.
De Leo V; Fulghesu AM; la Marca A; Morgante G; Pasqui L; Talluri B; Torricelli M; Caruso A
Gynecol Endocrinol; 2000 Dec; 14(6):411-6. PubMed ID: 11228061
[TBL] [Abstract][Full Text] [Related]
9. Treatment of moderate and severe hirsutism by gonadotropin-releasing hormone agonists in women with polycystic ovary syndrome and idiopathic hirsutism.
Falsetti L; Pasinetti E
Fertil Steril; 1994 May; 61(5):817-22. PubMed ID: 8174716
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effects of ovarian cauterization and gonadotropin-releasing hormone agonist and oral contraceptive therapy combination on endocrine changes in women with polycystic ovary disease.
Taskin O; Yalcinoglu AI; Kafkasli A; Burak F; Ozekici U
Fertil Steril; 1996 Jun; 65(6):1115-8. PubMed ID: 8641482
[TBL] [Abstract][Full Text] [Related]
11. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
Elkind-Hirsch KE; Anania C; Malinak R
J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
[TBL] [Abstract][Full Text] [Related]
12. The influence of combined cyproterone acetate-ethinyl oestradiol therapy on serum levels of dehydroepiandrosterone, androstenedione, and testosterone in hirsute women.
Frölich M; Lachinsky N; Moolenaar AJ
Acta Endocrinol (Copenh); 1977 Feb; 84(2):333-42. PubMed ID: 138326
[TBL] [Abstract][Full Text] [Related]
13. Oral contraceptive pills, gonadotropin-releasing hormone agonists, or use in combination for treatment of hirsutism: a clinical research center study.
Carr BR; Breslau NA; Givens C; Byrd W; Barnett-Hamm C; Marshburn PB
J Clin Endocrinol Metab; 1995 Apr; 80(4):1169-78. PubMed ID: 7714086
[TBL] [Abstract][Full Text] [Related]
14. Gonadotropin-releasing hormone agonist (GnRH-A) in hirsutism.
Falsetti L; Pasinetti E; Ceruti D
Acta Eur Fertil; 1994; 25(5):303-6. PubMed ID: 7660719
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism.
Sahin Y; Dilber S; Keleştimur F
Fertil Steril; 2001 Mar; 75(3):496-500. PubMed ID: 11239530
[TBL] [Abstract][Full Text] [Related]
16. Effects of a low-dose estrogen-antiandrogen combination (Diane-35) on clinical signs of androgenization, hormone profile and ovarian size in patients with polycystic ovary syndrome.
Prelević GM; Würzburger MI; Balint-Perić L; Puzigaća Z
Gynecol Endocrinol; 1989 Dec; 3(4):269-80. PubMed ID: 2516704
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy of low dose flutamide plus Diane-35 in the treatment of idiopathic hirsutism and polycystic ovary syndrome.
Boztosun A; Açmaz G; Ozturk A; Müderris II
Ginekol Pol; 2013 Apr; 84(4):258-62. PubMed ID: 23700857
[TBL] [Abstract][Full Text] [Related]
18. Comparison of cyproterone acetate plus ethinyl estradiol and finasteride in the treatment of hirsutism.
Sahin Y; Bayram F; Keleştimur F; Müderris I
J Endocrinol Invest; 1998 Jun; 21(6):348-52. PubMed ID: 9699125
[TBL] [Abstract][Full Text] [Related]
19. Finasteride versus cyproterone acetate-estrogen regimens in the treatment of hirsutism.
Beigi A; Sobhi A; Zarrinkoub F
Int J Gynaecol Obstet; 2004 Oct; 87(1):29-33. PubMed ID: 15464773
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism.
Batukan C; Muderris II
Fertil Steril; 2006 Feb; 85(2):436-40. PubMed ID: 16595223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
